G1 Therapeutics (Nasdaq:GTHX) - Aandelenkoers, Nieuws & Analyse

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

GTHX Overzicht aandelen

A commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States.

Over het bedrijf

GTHX fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	6/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 99.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 67.23% per jaar groeien

De winst is de afgelopen 5 jaar met 9.2% per jaar gegroeid

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

G1 Therapeutics, Inc. Concurrenten

ADC Therapeutics

NYSE:ADCT

US$288.1m

TScan Therapeutics

NasdaqGM:TCRX

US$302.0m

Sutro Biopharma

NasdaqGM:STRO

US$360.6m

Harpoon Therapeutics

NasdaqCM:HARP

US$492.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor G1 Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$7.15
52 Week Hoogtepunt	US$7.19
52 Week Laag	US$1.08
Bèta	1.68
11 maand verandering	0.85%
3 maanden verandering	182.61%
1 Jaar Verandering	433.58%
33 jaar verandering	-52.55%
5 jaar verandering	-78.80%
Verandering sinds IPO	-52.33%

Recent nieuws en updates

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

Rendement voor aandeelhouders

	GTHX	US Biotechs	US Markt
7D	0.3%	-1.3%	3.9%
1Y	433.6%	22.8%	33.2%

Rendement versus industrie: GTHX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 22.8 % opleverde.

Rendement versus markt: GTHX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 33.2 %.

Prijsvolatiliteit

Is GTHX's price volatile compared to industry and market?
GTHX volatility
GTHX Average Weekly Movement	19.9%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van GTHX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 20% ) van GTHX is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	100	Jack Bailey	www.g1therapeutics.com

G1 Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van G1 Therapeutics zich tot de beurswaarde?
GTHX fundamentele statistieken
Marktkapitalisatie	US$378.17m
Inkomsten(TTM)	-US$44.77m
Inkomsten(TTM)	US$58.20m

6.5x

P/S-verhouding

-8.4x

Koers/Winstverhouding

Is GTHX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GTHX resultatenrekening (TTM)
Inkomsten	US$58.20m
Kosten van inkomsten	US$6.14m
Brutowinst	US$52.05m
Overige uitgaven	US$96.82m
Inkomsten	-US$44.77m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.85
Brutomarge	89.44%
Nettowinstmarge	-76.93%
Schuld/Eigen Vermogen Verhouding	180.2%

Hoe presteerde GTHX op de lange termijn?

Bekijk historische prestaties en vergelijking

This company has been acquired

GTHX Overzicht aandelen

Beloningen

Risicoanalyse

G1 Therapeutics, Inc. Concurrenten

NYSE:ADCT

US$288.1m

NasdaqGM:TCRX

US$302.0m

NasdaqGM:STRO

US$360.6m

NasdaqCM:HARP

US$492.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to US$0.39 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.

New major risk - Share price stability

Recent updates

G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to US$0.39 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.

New major risk - Share price stability

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target decreased by 10.0% to US$7.50

G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting

CEO, President & Director recently sold US$178k worth of stock

Consensus estimates of losses per share improve by 18%

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

G1 Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

G1 Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 22%

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

G1 Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Price target decreased by 12% to US$8.33

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC

CEO, President & Director recently sold US$108k worth of stock

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023

New minor risk - Share price stability

G1 Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023

Consensus EPS estimates upgraded to US$0.96 loss

Price target decreased by 21% to US$8.80

New minor risk - Market cap size

New minor risk - Profitability

No longer forecast to breakeven

Consensus estimates of losses per share improve by 29%

G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics Announces Appointment of Monica Thomas as Chief Compliance Officer

Forecast to breakeven in 2025

G1 Therapeutics, Inc. Presents New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate

Consensus revenue estimates increase by 26%

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2023